265 related articles for article (PubMed ID: 22761788)
61. Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis.
Cochereau D; Georgin-Lavialle S; Maisonobe T; Dubourg O; Melboucy-Belkhir S; Hermine O; Aouba A
Joint Bone Spine; 2014 Jul; 81(4):362-5. PubMed ID: 24709000
[TBL] [Abstract][Full Text] [Related]
62. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
Robak T
Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
[TBL] [Abstract][Full Text] [Related]
63. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
64. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
65. Pharmacokinetics of alemtuzumab and the relevance in clinical practice.
Elter T; Molnar I; Kuhlmann J; Hallek M; Wendtner C
Leuk Lymphoma; 2008 Dec; 49(12):2256-62. PubMed ID: 19052972
[TBL] [Abstract][Full Text] [Related]
66. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.
Lim CK; Sun L; Feng Q; Law P; Chua WT; Lim SN; Hwang WY
J Hematol Oncol; 2008 Oct; 1():19. PubMed ID: 18947412
[TBL] [Abstract][Full Text] [Related]
67. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Gorin NC; Isnard F; Garderet L; Ikhlef S; Corm S; Quesnel B; Legrand O; Cachanado M; Rousseau A; Laporte JP
Eur J Haematol; 2013 Oct; 91(4):315-21. PubMed ID: 23738686
[TBL] [Abstract][Full Text] [Related]
68. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
Reiff A; Shaham B; Weinberg KI; Crooks GM; Parkman R
J Clin Immunol; 2011 Aug; 31(4):615-22. PubMed ID: 21541793
[TBL] [Abstract][Full Text] [Related]
69. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
70. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
[TBL] [Abstract][Full Text] [Related]
71. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
72. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
73. CD52 expression in hairy cell leukemia.
Quigley MM; Bethel KJ; Sharpe RW; Saven A
Am J Hematol; 2003 Dec; 74(4):227-30. PubMed ID: 14635201
[TBL] [Abstract][Full Text] [Related]
74. CD52 gene polymorphism and its potential effect on the response to alemtuzumab in renal transplant recipients.
Oko A; Wyrwicz LS; Glyda M; Idasiak-Piechocka I; Bińczak-Kuleta A; Kaczmarczyk M; Drozd A; Ciechanowicz A; Czekalski S
Ann Acad Med Stetin; 2009; 55(2):22-6. PubMed ID: 20349607
[TBL] [Abstract][Full Text] [Related]
75. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
76. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
[TBL] [Abstract][Full Text] [Related]
77. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
78. Anti-CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems.
Barbour M; Wood R; Harte T; Bushell TJ; Jiang HR
Immunology; 2022 Mar; 165(3):312-327. PubMed ID: 34826154
[TBL] [Abstract][Full Text] [Related]
79. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
[TBL] [Abstract][Full Text] [Related]
80. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
